Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

MLA

Kazunori Utsunomiya, et al. “Safety and Efficacy of Tofogliflozin in Japanese Patients with Type 2 Diabetes Mellitus in Real‐world Clinical Practice: Results of 3‐month Interim Analysis of a Long‐term Post‐marketing Surveillance Study (J‐STEP/LT).” Journal of Diabetes Investigation, vol. 10, no. 5, Sept. 2019, pp. 1272–83. EBSCOhost, https://doi.org/10.1111/jdi.13017.

APA

Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, & Kohei Kaku. (2019). Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation, 10(5), 1272–1283. https://doi.org/10.1111/jdi.13017

Chicago

Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, and Kohei Kaku. 2019. “Safety and Efficacy of Tofogliflozin in Japanese Patients with Type 2 Diabetes Mellitus in Real‐world Clinical Practice: Results of 3‐month Interim Analysis of a Long‐term Post‐marketing Surveillance Study (J‐STEP/LT).” Journal of Diabetes Investigation 10 (5): 1272–83. doi:10.1111/jdi.13017.